Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity.

Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ, Deng FH, Nie B, Jiang B.

Inflamm Bowel Dis. 2014 Aug;20(8):1407-15. doi: 10.1097/MIB.0000000000000057.

PMID:
24983982
2.

Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies.

Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, Hu PJ, Chen MH.

Inflamm Bowel Dis. 2012 Oct;18(10):1894-9. doi: 10.1002/ibd.22861. Epub 2012 Jan 11.

PMID:
22238138
3.

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.

D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P.

Inflamm Bowel Dis. 2012 Dec;18(12):2218-24. doi: 10.1002/ibd.22917. Epub 2012 Feb 16.

PMID:
22344983
4.

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R.

Health Technol Assess. 2013 Nov;17(55):xv-xix, 1-211. doi: 10.3310/hta17550. Review.

5.

Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.

Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B.

Inflamm Bowel Dis. 2014 Feb;20(2):307-14. doi: 10.1097/01.MIB.0000438428.30800.a6.

PMID:
24374878
6.

Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.

Nancey S, Boschetti G, Moussata D, Cotte E, Peyras J, Cuerq C, Haybrard J, Charlois AL, Mialon A, Chauvenet M, Stroeymeyt K, Kaiserlian D, Drai J, Flourié B.

Inflamm Bowel Dis. 2013 Apr;19(5):1043-52. doi: 10.1097/MIB.0b013e3182807577.

PMID:
23511035
7.

Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy.

von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, Paraskeva P, Tekkis PP.

Am J Gastroenterol. 2007 Apr;102(4):803-13. Epub 2007 Feb 23.

PMID:
17324124
8.

Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.

Yang Z, Clark N, Park KT.

Clin Gastroenterol Hepatol. 2014 Feb;12(2):253-62.e2. doi: 10.1016/j.cgh.2013.06.028. Epub 2013 Jul 21.

9.

Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.

Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S.

Inflamm Bowel Dis. 2008 May;14(5):669-73. doi: 10.1002/ibd.20376.

PMID:
18240279
10.

Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.

Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP.

Mol Med Rep. 2014 Jul;10(1):522-6. doi: 10.3892/mmr.2014.2180. Epub 2014 Apr 24.

PMID:
24788223
11.

Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.

Am J Gastroenterol. 2008 Jan;103(1):162-9. Epub 2007 Oct 4.

PMID:
17916108
12.

The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease.

Henderson P, Casey A, Lawrence SJ, Kennedy NA, Kingstone K, Rogers P, Gillett PM, Wilson DC.

Am J Gastroenterol. 2012 Jun;107(6):941-9. doi: 10.1038/ajg.2012.33. Epub 2012 Feb 28.

PMID:
22370604
13.

Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease.

Aomatsu T, Yoden A, Matsumoto K, Kimura E, Inoue K, Andoh A, Tamai H.

Dig Dis Sci. 2011 Aug;56(8):2372-7. doi: 10.1007/s10620-011-1633-y. Epub 2011 Mar 11.

PMID:
21394462
14.

Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.

Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R.

Inflamm Bowel Dis. 2007 Nov;13(11):1374-8.

PMID:
17577247
15.

Fecal pyruvate kinase is not suitable for discrimination between inflammatory bowel disease exacerbation and acute gastroenteritis.

Czub E, Nowak JK, Moczko J, Mankowski P, Lisowska A, Banaszkiewicz A, Banasiewicz T, Walkowiak J.

Dev Period Med. 2015 Apr-Jun;19(2):167-73.

16.

[Fecal calprotectin: a diagnostic tool for inflammatory bowel disease].

Fraga M, Godat S, Nydegger A, Moradpour D, Schoepfer AM.

Rev Med Suisse. 2012 Sep 5;8(352):1669-70, 1672-3. French.

PMID:
22988727
17.

Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.

Voiosu T, Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B.

J Gastrointestin Liver Dis. 2014 Sep;23(3):273-8. doi: 10.15403/jgld.2014.1121.233.thv.

18.

Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity.

Czub E, Nowak JK, Szaflarska-Poplawska A, Grzybowska-Chlebowczyk U, Landowski P, Moczko J, Adamczak D, Mankowski P, Banasiewicz T, Plawski A, Walkowiak J.

Acta Biochim Pol. 2014;61(1):99-102. Epub 2014 Mar 20.

19.

Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases.

Inoue K, Aomatsu T, Yoden A, Okuhira T, Kaji E, Tamai H.

J Gastroenterol Hepatol. 2014;29(7):1406-12. doi: 10.1111/jgh.12578.

PMID:
24635100
20.

Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.

Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T.

Inflamm Bowel Dis. 2012 Nov;18(11):2011-7. doi: 10.1002/ibd.22863. Epub 2012 Jan 4.

PMID:
22223566

Supplemental Content

Support Center